A phase I/ II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase I/ II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort

Published:2021-01-28 Issue:4 Volume:96 Page:428-435
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Berdeja Jesus G.¹²^ORCID,Gregory Tara K.¹³,Faber Edward A.¹⁴,Hart Lowell L.¹⁵,Mace Joseph R.¹⁶,Arrowsmith Edward R.¹⁷,Flinn Ian W.¹²^ORCID,Matous Jeffrey V.¹³

Affiliation:

1. Sarah Cannon Research Institute Nashville Tennessee

2. Tennessee Oncology PLLC Nashville Tennessee

3. Colorado Blood Cancer Institute Denver Colorado

4. Oncology Hematology Care Cincinnati Ohio

5. Florida Cancer Specialists Fort Myers Florida

6. Florida Cancer Specialists St. Petersburg Florida

7. Tennessee Oncology PLLC Chattanooga Tennessee

Funder

Novartis

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26088

Reference29 articles.

1. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents

2. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

3. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

4. Molecular sequelae of histone deacetylase inhibition in human malignant B cells

5. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rediscovering hemostasis abnormalities in multiple myeloma: The new era;Heliyon;2024-07

2. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives;Experimental Hematology & Oncology;2024-04-23

3. New trends in synthetic drugs and natural products targeting 20S proteasomes in cancers;Bioorganic Chemistry;2023-04

4. Panobinostat (LBH589) increase survival in adult xenografic model of acute lymphoblastic leukemia with t(4;11) but promotes antagonistic effects in combination with MTX and 6MP;Medical Oncology;2022-09-29

5. Pathogenesis and treatment of multiple myeloma;MedComm;2022-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3